Government and Business Representatives Discuss Future of Russian Pharmaceutical Industry


The ‘#SPIEFtime: Challenges the State and the Pharmaceutical Industry Face Today’ business breakfast took place online at 10:00 a.m. on 2 June. The event was organized by the Roscongress Foundation and the Content Foundation for the Development of Expert and Analytical Activities. Given the coronavirus pandemic, the Roscongress Foundation supported the regular tradition and held a business breakfast with representatives of the government, the public and the pharmaceutical industry online during the days on which the SPIEF is traditionally held. The event was supported by the Subcommittee on the Circulation of Medicine and the Development of the Pharmaceutical and Medical Industries of the Health Protection Committee of the State Duma of the Russian Federation. The CDA served as an organizational partner.

The event was attended by Alla Samoilova, Director of the Federal Service for Surveillance in Healthcare and Social Development (Roszdravnadzor); Yelena Maksimkina, Director of the Department of Drug Supply and Regulation of Medical Devices at the Ministry of Health of the Russian Federation; Grigory Ivliev, Head of the Federal Service for Intellectual Property; Matthias Wernicke, CEO of Merck in the Russian Federation and CIS countries, as well as pharmaceutical industry representatives . Alexander Petrov, the Chairman of the Subcommittee on the Circulation of Medicine and the Development of the Pharmaceutical and Medical Industries of the Health Protection Committee of the State Duma of the Russian Federation, moderated the event.

The agenda of the event was formed on the basis of strategies pursued both within the pharmaceutical industry and at the level of the relevant authorities of state agencies in response to the challenges posed by the coronavirus pandemic. The business breakfast participants discussed possible support measures for the pharmaceutical industry by the government, the localization of production as a strategy to ensure the uninterrupted availability of drugs, the simplification of the procedure for registering medicines and introducing new drugs into clinical practice and other issues. The Federal Service for Intellectual Property (Rospatent) announced the creation of a unified Eurasian register of pharmacologically active substances as a progressive measure.

“It is extremely important for us to both guarantee patent protection to all inventors and patent holders and have effective tools for such protection as well. So I hope that a unified Eurasian registry will be created soon and will be maintained by Rospatent and the Ministry of Health. The copyright holder will be entitled to provide information on the rights that will be available in the register. This will make it possible to correlate them with the data on previously registered drugs and patents, and then determine the market functioning of the newly registered funds. In addition, the registry will help us fight the coronavirus since it will ensure the prompt introduction of drugs and test systems on the market as well as protect the patent holders’ rights”, Ivliev said in comments on the current initiative.

The event participants noted how pharmaceutical market players and the public authorities had engaged in a productive dialogue and maintained communication, which became an essential factor to the success achieved during the pandemic. “Both parties are looking forward to continuing such a dialogue. Market participants and government officials agreed on the need to consolidate the best practices of cooperation gained during the pandemic and to expand it in the post-crisis period”, said Anastasia Stolkova, Director of the Healthy Life project and First Deputy CEO for Development at the Roscongress Foundation.